Development and In Vitro Evaluation of Oral Capsules from Antiaris: A Convenient Substitute for Peripheral Neuropathy
Antiaris is a monoherbal decoction produced by the Centre for Plant Medicine Research (CPMR), Mampong-Akuapem, Ghana. It is prepared from the stem bark of Antiaris africana Engl. (Moraceae), prescribed, and dispensed to patients for the management of nervous disorders. This current formulation prese...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Advances in Pharmacological and Pharmaceutical Sciences |
| Online Access: | http://dx.doi.org/10.1155/2022/5340953 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832562234699546624 |
|---|---|
| author | Mary-Ann Archer Doris Kumadoh Samuel Nii-Bortier Gaizer Adelaide Mensah Jonathan Jato Micheal Odoi Kyene Susana Oteng Mintah Genevieve Naana Yeboah Paul kwesi Sodzi Ofosua Adi-Dako |
| author_facet | Mary-Ann Archer Doris Kumadoh Samuel Nii-Bortier Gaizer Adelaide Mensah Jonathan Jato Micheal Odoi Kyene Susana Oteng Mintah Genevieve Naana Yeboah Paul kwesi Sodzi Ofosua Adi-Dako |
| author_sort | Mary-Ann Archer |
| collection | DOAJ |
| description | Antiaris is a monoherbal decoction produced by the Centre for Plant Medicine Research (CPMR), Mampong-Akuapem, Ghana. It is prepared from the stem bark of Antiaris africana Engl. (Moraceae), prescribed, and dispensed to patients for the management of nervous disorders. This current formulation presents notable challenges in patients’ adherence to treatment regimen due to its bulkiness and bitterness. These challenges have resulted in a decrease in therapeutic outcome. This study sought to transform Antiaris into oral capsules to mask its bitter taste and reduce bulkiness of the product to improve patients’ convenience. In this study, four (4) conventional release capsule formulations were successfully prepared from the decoction via wet granulation using corn starch, lactose, light magnesium carbonate (LMC), and microcrystalline cellulose (MCC) and labelled A01, A02, A03, and A04 respectively. The drug-excipient compatibility studies on A01, A02, A03, and A04 were investigated using Fourier transform infrared (FTIR) spectroscopy. The flow properties of the granules as well as the quality assessment of the formulations such as dissolution, disintegration, uniformity of weight, and assay tests were evaluated using pharmacopoeial and nonpharmacopoeial methods. Appropriate models were used to investigate the difference factor (f1) and similarity factor (f2) of the dissolution profiles of the formulations and Antiaris. From the study, all formulated granules had excellent flow properties with Carr’s index from 7.83 to 9.56%, Hausner’s ratio from 1.09 to 1.10, and angle of repose from 25.13 to 27.87°. Drug-excipient compatibility studies demonstrated no interaction between extract and used excipients. All formulations passed the uniformity of weight, disintegration, assay, and dissolution tests. Formulation A02 had the highest dissolution efficiency of 100.12%, while A03 recorded the least value of 97.22% in the 1 h dissolution studies. A comparison of their various dissolution profiles, respectively, to that of its decoction demonstrated their similarity, since, in all comparisons, f2 < 15 and f1 > 50. This implies that, any of these four formulations could be a good substitute for Antiaris. |
| format | Article |
| id | doaj-art-035b48b65371451783c2714c4439bbb0 |
| institution | Kabale University |
| issn | 2633-4690 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Pharmacological and Pharmaceutical Sciences |
| spelling | doaj-art-035b48b65371451783c2714c4439bbb02025-02-03T01:22:58ZengWileyAdvances in Pharmacological and Pharmaceutical Sciences2633-46902022-01-01202210.1155/2022/5340953Development and In Vitro Evaluation of Oral Capsules from Antiaris: A Convenient Substitute for Peripheral NeuropathyMary-Ann Archer0Doris Kumadoh1Samuel Nii-Bortier Gaizer2Adelaide Mensah3Jonathan Jato4Micheal Odoi Kyene5Susana Oteng Mintah6Genevieve Naana Yeboah7Paul kwesi Sodzi8Ofosua Adi-Dako9Department of PharmaceuticsDepartment of Pharmaceutics and Quality ControlDepartment of Drug Production and Quality AssuranceDepartment of Drug Production and Quality AssuranceDepartment of Drug Production and Quality AssuranceDepartment of Pharmaceutics and Quality ControlDepartment of MicrobiologyDepartment of Pharmaceutics and Quality ControlDepartment of Pharmaceutical SciencesDepartment of Pharmaceutics and MicrobiologyAntiaris is a monoherbal decoction produced by the Centre for Plant Medicine Research (CPMR), Mampong-Akuapem, Ghana. It is prepared from the stem bark of Antiaris africana Engl. (Moraceae), prescribed, and dispensed to patients for the management of nervous disorders. This current formulation presents notable challenges in patients’ adherence to treatment regimen due to its bulkiness and bitterness. These challenges have resulted in a decrease in therapeutic outcome. This study sought to transform Antiaris into oral capsules to mask its bitter taste and reduce bulkiness of the product to improve patients’ convenience. In this study, four (4) conventional release capsule formulations were successfully prepared from the decoction via wet granulation using corn starch, lactose, light magnesium carbonate (LMC), and microcrystalline cellulose (MCC) and labelled A01, A02, A03, and A04 respectively. The drug-excipient compatibility studies on A01, A02, A03, and A04 were investigated using Fourier transform infrared (FTIR) spectroscopy. The flow properties of the granules as well as the quality assessment of the formulations such as dissolution, disintegration, uniformity of weight, and assay tests were evaluated using pharmacopoeial and nonpharmacopoeial methods. Appropriate models were used to investigate the difference factor (f1) and similarity factor (f2) of the dissolution profiles of the formulations and Antiaris. From the study, all formulated granules had excellent flow properties with Carr’s index from 7.83 to 9.56%, Hausner’s ratio from 1.09 to 1.10, and angle of repose from 25.13 to 27.87°. Drug-excipient compatibility studies demonstrated no interaction between extract and used excipients. All formulations passed the uniformity of weight, disintegration, assay, and dissolution tests. Formulation A02 had the highest dissolution efficiency of 100.12%, while A03 recorded the least value of 97.22% in the 1 h dissolution studies. A comparison of their various dissolution profiles, respectively, to that of its decoction demonstrated their similarity, since, in all comparisons, f2 < 15 and f1 > 50. This implies that, any of these four formulations could be a good substitute for Antiaris.http://dx.doi.org/10.1155/2022/5340953 |
| spellingShingle | Mary-Ann Archer Doris Kumadoh Samuel Nii-Bortier Gaizer Adelaide Mensah Jonathan Jato Micheal Odoi Kyene Susana Oteng Mintah Genevieve Naana Yeboah Paul kwesi Sodzi Ofosua Adi-Dako Development and In Vitro Evaluation of Oral Capsules from Antiaris: A Convenient Substitute for Peripheral Neuropathy Advances in Pharmacological and Pharmaceutical Sciences |
| title | Development and In Vitro Evaluation of Oral Capsules from Antiaris: A Convenient Substitute for Peripheral Neuropathy |
| title_full | Development and In Vitro Evaluation of Oral Capsules from Antiaris: A Convenient Substitute for Peripheral Neuropathy |
| title_fullStr | Development and In Vitro Evaluation of Oral Capsules from Antiaris: A Convenient Substitute for Peripheral Neuropathy |
| title_full_unstemmed | Development and In Vitro Evaluation of Oral Capsules from Antiaris: A Convenient Substitute for Peripheral Neuropathy |
| title_short | Development and In Vitro Evaluation of Oral Capsules from Antiaris: A Convenient Substitute for Peripheral Neuropathy |
| title_sort | development and in vitro evaluation of oral capsules from antiaris a convenient substitute for peripheral neuropathy |
| url | http://dx.doi.org/10.1155/2022/5340953 |
| work_keys_str_mv | AT maryannarcher developmentandinvitroevaluationoforalcapsulesfromantiarisaconvenientsubstituteforperipheralneuropathy AT doriskumadoh developmentandinvitroevaluationoforalcapsulesfromantiarisaconvenientsubstituteforperipheralneuropathy AT samuelniibortiergaizer developmentandinvitroevaluationoforalcapsulesfromantiarisaconvenientsubstituteforperipheralneuropathy AT adelaidemensah developmentandinvitroevaluationoforalcapsulesfromantiarisaconvenientsubstituteforperipheralneuropathy AT jonathanjato developmentandinvitroevaluationoforalcapsulesfromantiarisaconvenientsubstituteforperipheralneuropathy AT michealodoikyene developmentandinvitroevaluationoforalcapsulesfromantiarisaconvenientsubstituteforperipheralneuropathy AT susanaotengmintah developmentandinvitroevaluationoforalcapsulesfromantiarisaconvenientsubstituteforperipheralneuropathy AT genevievenaanayeboah developmentandinvitroevaluationoforalcapsulesfromantiarisaconvenientsubstituteforperipheralneuropathy AT paulkwesisodzi developmentandinvitroevaluationoforalcapsulesfromantiarisaconvenientsubstituteforperipheralneuropathy AT ofosuaadidako developmentandinvitroevaluationoforalcapsulesfromantiarisaconvenientsubstituteforperipheralneuropathy |